基本信息
浏览量:7
职业迁徙
个人简介
My CCOM research program is primarily directed to 1) development of novel, broad-spectrum anti-infectives without microbial resistance and 2) studies of newly described microbial illnesses, recently focusing on causes of type II diabetes. My clinical/basic science collaborators and I have described/developed novel treatments for 19 new human illnesses, including staphylococcal toxic shock syndrome (TSS; 1981), post-influenza TSS (1987), staphylococcal purpura fulminans (2005), extreme pyrexia syndrome (2009), and streptococcal TSS (flesh-eating disease; 1987). These studies saved the U.S. healthcare system over $500 billion over the past 30 years. My laboratory has a long history of studies of staphylococcal, streptococcal, and enterococcal superantigen-like molecules in sensitive animal models and in humans. Recently, we have fulfilled Koch’s postulates, showing the causal role of S. aureus and its superantigens in development of Type II diabetes. I have recently developed a toxoid vaccine that protects rabbit models from all S. aureus illnesses. I am the Chief Scientific Officer and co-founder of a small biotechnology company, Hennepin Life Sciences, whose goal is to prevent and treat mucosal and skin infections through use of glycerol monolaurate (GML). Active projects include: 1) use of GML to treat and prevent simultaneous bacterial vaginosis and candidiasis as its first indication; 2) use in prevention of HIV transmission vaginally alone and in concert with approved anti-retroviral agents; 3) use to decolonize nasal mucosa; 4) use to prevent infections with Herpes Simplex Viruses; 5) use to prevent catheter-associated urinary tract infections; and 6) use to reduce skin Staphylococcus aureus associated with atopic dermatitis and diabetes. Our prior research established the exceptional safety of GML in both rhesus macaques and humans; this was affirmed in FDA responses to a pre-IND submission. We have also demonstrated in vivo (in rhesus macaques and women) that GML is antimicrobial for pathogens, while not affecting normal flora lactobacilli.
研究兴趣
论文共 434 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ania Stolarczyk, Eleanor Pope St. John, Fatima Bawany, Calla Fahey,Francisco Tausk,Patrick Schlievert,Lisa Beck,Takeshi Yoshida
Journal of the American Academy of Dermatologyno. 3 (2024): AB264
H Mark Kenney,Takeshi Yoshida, Evgeny Berdyshev,Agustin Calatroni,Steven R Gill,Eric L Simpson,Stephanie Lussier,Mark Boguniewicz, Tissa Hata,Zelma C Chiesa Fuxench, Anna De Benedetto, Peck Y Ong,Justin Ko,Wendy Davidson,Gloria David,Patrick M Schlievert,Donald Y M Leung,Lisa A Beck
The Journal of allergy and clinical immunology (2024)
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYno. 2 (2024): AB255-AB255
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYno. 2 (2024): AB68-AB68
J. Hill,S. Kilgore, A. Rozen, M. Regan, E. Arnold, N. Woo, A. Pamatmat,C. Zirbes,A. Moustafa,P. Planet,P. Schlievert, A. Fischer
Journal of Cystic Fibrosis (2023)
Microbiology spectrumno. 6 (2023)
Microbiology spectrumno. 5 (2023)
Eric L. Simpson,Patrick M. Schlievert,Takeshi Yoshida,Stephanie Lussier,Mark Boguniewicz,Tissa Hata,Zelma Fuxench,Anna De Benedetto,Peck Y. Ong,Justin Ko,Agustin Calatroni,Amanda K. Rudman Spergel,Marshall Plaut,Sally A. Quataert,Samuel H. Kilgore,Liam Peterson,Ann L. Gill,Gloria David,Tim Mosmann,Steven R. Gill,Donald Y. M. Leung,Lisa A. Beck
The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunologyno. 5 (2023): 1179-1195
E. Simpson,P. Schlievert, T. Yoshida,S. Lussier,M. Boguniewicz,T. Hata,Z. C. Chiesa Fuxench,A. De Benedetto,P. Ong,J. Ko, A. Calatroni,A. Rudman Spergel,M. Plaut,S. Quataert,S. Kilgore,L. Peterson,A. Gill,G. David,T. Mosmann,S. Gill, D. Leung, L. Beck
加载更多
作者统计
#Papers: 432
#Citation: 26011
H-Index: 79
G-Index: 149
Sociability: 7
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn